Inhaler therapy is a core treatment for asthma management, delivering medication directly to the respiratory tract through inhalation devices to relieve acute symptoms or control chronic inflammation. This therapy effectively reduces airway narrowing, decreases hyperresponsiveness, and improves lung function.
Compared to oral or intravenous medications, inhalation delivery increases local drug concentration while reducing systemic side effects. The treatment goals include preventing symptom attacks, reducing the frequency of emergency medication use, and enhancing patients' quality of life.
Primarily divided into two categories: rapid relief (bronchodilators) and long-term control (inhaled corticosteroids). Short-acting β2-agonists (SABA) such as salbutamol quickly relax airway smooth muscles; inhaled corticosteroids (ICS) like budesonide are used continuously to reduce chronic inflammation.
Combination therapy is common in moderate to severe asthma, such as fixed-dose combinations of ICS and long-acting bronchodilators (LABA). Additionally, new biological inhalers target specific inflammatory mediators, offering precise treatment options.
Suitable for asthma patients of all ages, including symptom relief during acute attacks and long-term airway inflammation control. It can also be used to prevent exercise-induced bronchoconstriction or symptoms triggered by environmental stimuli.
Some formulations are also applicable for chronic obstructive pulmonary disease (COPD) treatment, but require physician assessment. Severe asthma patients may need combined inhaler therapy with systemic corticosteroids or other biological agents.
Before use, the device should be cleaned and the medication dose checked. Proper steps include exhaling fully, holding breath for several seconds after inhalation to ensure even distribution of medication in the airways. For first-time use or device change, demonstration by healthcare personnel is recommended.
Dosage is adjusted based on severity: acute attacks may require SABA every 4-6 hours; ICS is usually used regularly 1-2 times daily. Physicians will adjust maintenance doses based on control indicators such as PEF values.
Long-term regular use can reduce hospitalization and emergency visits, with studies showing ICS can decrease inflammatory markers by over 70%. Pediatric-specific nebulizers (such as mask designs) improve treatment compliance in young children.
Short-term side effects include dry mouth, throat irritation, or cough, which can be minimized by rinsing the mouth to reduce fungal infections. Long-term ICS use may cause hoarseness or oral ulcers, requiring regular oral care.
Serious risks include: Overuse of SABA may induce palpitations or tremors; long-term monotherapy with LABA may increase the risk of asthma deterioration. Special populations such as patients with severe heart disease should be carefully evaluated.
Contraindications include allergies to medication components or device materials. Lung function should be monitored regularly during use, and concurrent use with other aerosolized medications should be avoided to prevent drug residue. Pregnant or breastfeeding women should evaluate risks and benefits; children should be used under adult supervision. Patients with a history of arrhythmias should choose low-stimulation bronchodilators.
Combining with oral steroids may increase the risk of vocal cord edema, requiring dose adjustments. When using theophylline, inhaled bronchodilators may increase palpitations. When used with antihistamines or anticholinergic drugs, timing should be considered. Physicians will assess potential interactions with antihypertensive or diabetic medications.
Clinical trials show that regular ICS use can reduce acute attacks by 50-70%, with an average improvement in FEV1 of 15-20%. Long-term studies confirm that proper inhaler use can reduce hospitalization rates by over 60%. Biological inhalers in severe asthma trials have reduced exacerbations by 40-60%. Patient education and correct inhalation technique directly influence treatment success rates.
Severe attacks may require short-term oral corticosteroids; long-term control options include oral leukotriene receptor antagonists. Severe asthma patients may need anti-IgE monoclonal antibodies or anti-IL-5 biological agents. However, these alternatives often carry more systemic side effects. Inhaler therapy remains the first-line treatment due to its targeted action and high benefit-to-risk ratio.
Proper inhaler use involves the following steps: clean the mouthpiece before use, shake the inhaler (if suspension), exhale fully, place lips tightly around the mouthpiece, press the inhaler while slowly inhaling deeply, hold breath for about ten seconds, then rinse the mouth. It is recommended that healthcare personnel demonstrate proper technique during initial use or use of a spacer device to improve medication delivery to the lungs. If symptoms do not improve, consult your healthcare provider for adjustments rather than increasing the dose on your own.
Does long-term use of inhaled corticosteroids affect bone health?The systemic absorption of inhaled corticosteroids is very low, so the risk of osteoporosis is relatively small. However, long-term high-dose use may require periodic bone density monitoring. Patients are advised to intake sufficient calcium and vitamin D, and engage in weight-bearing exercises such as walking or gymnastics to maintain bone health. If side effects are a concern, discuss alternative options with your doctor instead of stopping medication abruptly.
How should I adjust inhaler use during weather changes or air pollution?During air pollution or sudden temperature changes, it is recommended to carry a fast-acting bronchodilator for emergencies. If exposure to irritants (such as polluted air or pollen) is anticipated, use preventive medication 10-15 minutes beforehand. If symptoms occur frequently, record triggers and consult your healthcare provider for treatment adjustments rather than simply increasing rescue medication use.
How long does it take for inhaler therapy to show effects?Short-acting bronchodilators usually relieve symptoms within minutes, while controller medications (such as corticosteroid inhalers) require continuous use for 2-4 weeks to significantly reduce airway sensitivity. Patients should use controller medications regularly every day and monitor progress with indicators like peak flow measurements. If no improvement is observed after 6 weeks, seek medical evaluation promptly.
How can I prevent exercise-induced asthma during vigorous activity?Use a short-acting bronchodilator 15-30 minutes before exercise, and choose a temperature-controlled environment. Start with low-intensity activity and gradually increase intensity, avoiding strenuous activity in polluted or cold, dry weather. If chest tightness persists after exercise, consult your healthcare provider to adjust daily control medications, possibly increasing anti-inflammatory drugs.
%201.svg)
Copyright © 2025 MedFrontiers. All Rights Reserved.
